Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
WBO:VRTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USAVRTX.MexicoVX1.GermanyVRTX.AustriaVRTX34.BrazilVX1d.UKVRTX.Switzerland IPO Date
2017-05-22Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.64 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.17 | |||||
| Interest Coverage | 93.11 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 13.4 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.2 | |||||
| 3-Year EBITDA Growth Rate | 42 | |||||
| 3-Year EPS without NRI Growth Rate | 41.7 | |||||
| 3-Year FCF Growth Rate | 38.3 | |||||
| 3-Year Book Growth Rate | 32.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.55 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.83 | |||||
| 9-Day RSI | 53.77 | |||||
| 14-Day RSI | 55.94 | |||||
| 6-1 Month Momentum % | 13.3 | |||||
| 12-1 Month Momentum % | 9.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.14 | |||||
| Quick Ratio | 3.96 | |||||
| Cash Ratio | 3.35 | |||||
| Days Inventory | 149.73 | |||||
| Days Sales Outstanding | 55.79 | |||||
| Days Payable | 83.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.22 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.92 | |||||
| Operating Margin % | 47.04 | |||||
| Net Margin % | 35.4 | |||||
| ROE % | 24.46 | |||||
| ROA % | 18.74 | |||||
| ROIC % | 63.64 | |||||
| ROC (Joel Greenblatt) % | 301.1 | |||||
| ROCE % | 28.84 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.86 | |||||
| Forward PE Ratio | 22.12 | |||||
| PE Ratio without NRI | 26.86 | |||||
| Shiller PE Ratio | 69.32 | |||||
| Price-to-Owner-Earnings | 26.42 | |||||
| PEG Ratio | 0.29 | |||||
| PS Ratio | 9.52 | |||||
| PB Ratio | 5.8 | |||||
| Price-to-Tangible-Book | 6.51 | |||||
| Price-to-Free-Cash-Flow | 23.33 | |||||
| Price-to-Operating-Cash-Flow | 22.25 | |||||
| EV-to-EBIT | 18.22 | |||||
| EV-to-Forward-EBIT | 15.77 | |||||
| EV-to-EBITDA | 17.59 | |||||
| EV-to-Forward-EBITDA | 15.9 | |||||
| EV-to-Revenue | 8.35 | |||||
| EV-to-Forward-Revenue | 7.45 | |||||
| EV-to-FCF | 20.45 | |||||
| Price-to-Projected-FCF | 1.96 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.07 | |||||
| Price-to-Graham-Number | 2.79 | |||||
| Price-to-Net-Current-Asset-Value | 9.97 | |||||
| Price-to-Net-Cash | 14.11 | |||||
| Earnings Yield (Greenblatt) % | 5.49 | |||||
| Forward Rate of Return (Yacktman) % | 22.88 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9,050.679 | ||
| EPS (TTM) (€) | 12.361 | ||
| Beta | 0.06 | ||
| Volatility % | 23.61 | ||
| 14-Day RSI | 55.94 | ||
| 14-Day ATR (€) | 2.601628 | ||
| 20-Day SMA (€) | 328.2725 | ||
| 12-1 Month Momentum % | 9.3 | ||
| 52-Week Range (€) | 262.95 - 335.45 | ||
| Shares Outstanding (Mil) | 258.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vertex Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(WBO:VRTX)'s stock price today?
The current price of WBO:VRTX is €330.55. The 52 week high of WBO:VRTX is €335.45 and 52 week low is €262.95.
When is next earnings date of Vertex Pharmaceuticals Inc(WBO:VRTX)?
The next earnings date of Vertex Pharmaceuticals Inc(WBO:VRTX) is 2023-10-27 Est..
Does Vertex Pharmaceuticals Inc(WBO:VRTX) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(WBO:VRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers